Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study

被引:94
作者
Garinis, G. A. [1 ]
Fruci, B. [1 ]
Mazza, A. [1 ]
De Siena, M. [2 ]
Abenavoli, S. [2 ]
Gulletta, E. [3 ]
Ventura, V. [3 ]
Greco, M. [3 ]
Abenavoli, L. [4 ]
Belfiore, A. [1 ]
机构
[1] Magna Graecia Univ Catanzaro, Endocrinol Unit, Dept Clin & Expt Med, Catanzaro, Italy
[2] Azienda Osped Mater Domini, Hepatol Unit, Catanzaro, Italy
[3] Magna Graecia Univ Catanzaro, Clin Pathol Unit, Dept Clin & Expt Med, Catanzaro, Italy
[4] Magna Graecia Univ Catanzaro, Digest Physiopathol Unit, Dept Clin & Expt Med, Catanzaro, Italy
关键词
NAFLD; dietary treatment; metformin; metabolic syndrome; FATTY LIVER-DISEASE; PLACEBO-CONTROLLED TRIAL; INSULIN-RESISTANCE; METABOLIC SYNDROME; NONINVASIVE DIAGNOSIS; LIFE-STYLE; OPEN-LABEL; VITAMIN-E; STEATOHEPATITIS; PIOGLITAZONE;
D O I
10.1038/ijo.2010.40
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We aimed at evaluating whether the addition of low-dose metformin to dietary treatment could be an effective approach in nondiabetic patients with nonalcoholic fatty liver disease (NAFLD). Methods: We carried out a 6-month prospective study in a series of overweight or obese patients with ultrasonographic diagnosis of hepatic steatosis. In total, 50 patients were enrolled and randomized into two groups: the first group (n = 25) was given metformin (1 g per day) plus dietary treatment and the second group (n = 25) was given dietary treatment alone. Results: At the end of the study, the proportion of patients with echographic evidence of fatty liver was reduced in both the metformin (P<0.0001) and the diet group (P = 0.029). Moreover, patient body mass index and waist circumference significantly decreased in both groups (P<0.001). Fasting glucose, insulin resistance (evaluated as homeostasis model assessment of insulin resistance (HOMA-IR)) and serum adiponectin decreased in both groups, although these changes reached statistical significance only in the metformin group. In this group, HOMA-IR decreased from 3.3 +/- 1.6 to 2.4 +/- 1.2 (P = 0.003), whereas it decreased from 3.2 +/- 1.6 to 2.8 +/- 1.1 (not significant, NS) in the diet group. Similarly, the proportion of patients with impaired fasting glucose declined from 35 to 5% (P = 0.04) in the metformin and from 32 to 12% (NS) in the diet group. At baseline, similar to 40% of patients in both groups met the diagnostic criteria of metabolic syndrome. This proportion decreased to 20% in the metformin group (P = 0.008) and to 32% in the diet group (NS). Conclusions: In our 6-month prospective study, both low-dose metformin and dietary treatment alone ameliorated liver steatosis and metabolic derangements in patients with NAFLD. However, metformin was more effective than dietary treatment alone in normalizing several metabolic parameters in these patients. International Journal of Obesity (2010) 34, 1255-1264; doi: 10.1038/ijo.2010.40; published online 23 February 2010
引用
收藏
页码:1255 / 1264
页数:10
相关论文
共 54 条
[1]   Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis [J].
Aithal, Guruprasad P. ;
Thomas, James A. ;
Kaye, Philip V. ;
Lawson, Adam ;
Ryder, Stephen D. ;
Spendlove, Ian ;
Austin, Andrew S. ;
Freeman, Jan G. ;
Morgan, Linda ;
Weeber, Jonathan .
GASTROENTEROLOGY, 2008, 135 (04) :1176-1184
[2]  
Grundy Scott M, 2005, Crit Pathw Cardiol, V4, P198
[3]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[4]  
[Anonymous], 1998, Obes Res, V6, p51S
[5]   Diagnosing insulin resistance by simple quantitative methods in subiects with normal glucose metabolism [J].
Ascaso, JF ;
Pardo, S ;
Real, JT ;
Lorente, RI ;
Priego, A ;
Carmena, R .
DIABETES CARE, 2003, 26 (12) :3320-3325
[6]   A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [J].
Belfort, Renata ;
Harrison, Stephen A. ;
Brown, Kenneth ;
Darland, Celia ;
Finch, Joan ;
Hardies, Jean ;
Balas, Bogdan ;
Gastaldelli, Amalia ;
Tio, Fermin ;
Pulcini, Joseph ;
Berria, Rachele ;
Ma, Jennie Z. ;
Dwivedi, Sunil ;
Havranek, Russell ;
Fincke, Chris ;
DeFronzo, Ralph ;
Bannayan, George A. ;
Schenker, Steven ;
Cusi, Kenneth .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2297-2307
[7]   Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD) [J].
Bellentani, Stefano ;
Marino, Mariano .
ANNALS OF HEPATOLOGY, 2009, 8 :S4-S8
[8]   Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? [J].
Bugianesi, E ;
Zannoni, C ;
Vanni, E ;
Marzocchi, R ;
Marchesini, G .
DIGESTIVE AND LIVER DISEASE, 2004, 36 (03) :165-173
[9]   A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease [J].
Bugianesi, E ;
Gentilcore, E ;
Manini, R ;
Natale, S ;
Vanni, E ;
Villanova, N ;
David, E ;
Rizzetto, M ;
Marchesini, G .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (05) :1082-1090
[10]   Non-invasive diagnosis of steatosis and fibrosis [J].
Castera, L. .
DIABETES & METABOLISM, 2008, 34 (06) :674-679